Hello everyone. Welcome to the Faron Pharmaceuticals Oy Half-Year Report webcast. Apologies for the technical issues in the beginning, but I think we're now up and running and happy to be here with you. Next slide please. As a biotech, we will be making forward-looking statements. So, our standard disclaimer. Next slide please. For today's agenda, I will be taking you through the past key events and also the future outlook. Then our Chief Financial Officer, Jurriaan Dekkers, will be presenting the actual financial results, followed by a Q&A session. Next slide please. Okay, let's go to the key events of the first half. Next slide, please. First and foremost, there may be some newcomers to the story. So. A short introduction to Faron Pharmaceuticals Oy and high-risk myelodysplastic syndrome. First of all, Faron Pharmaceuticals Oy is a clinical-stage immunotherapy company with proven efficacy in phase two, demonstrating that we can overcome treatment resistance in some very difficult cancers. Our lead focus is on high-risk myelodysplastic syndrome, or HR MDS. It is a lethal form of leukemia causing severe anemia, severe infections and bleeding. And there have been no new treatments for the past 20 years. It is currently treated with a chemotherapy-like regimen named hypomethylating agents. The problem with hypomethylating agents is that the majority do not get a proper response, and eventually, basically everybody relapses and there is no approved second-line therapy. This is an orphan indication, but the market opportunity is significant. With 40,000 new patients each year in the US and main EU countries. Faron Pharmaceuticals' bexmarilimab is a first-in-class anti-Clever-1 antibody. It is one of the rare drugs that has actually shown that it can improve cancer cell killing, while also inducing the production of healthy blood cells in the bone marrow. And this is key for deep and durable responses and sustainable benefit for patients. So let's have a look at what this drug does. Next slide please. Again, this is a first-in-class anti-Clever-1 antibody. Number one, we activate the immune system through activating monocytes and macrophages. And now, number two: Myelodysplastic syndrome is a cancer of the macrophage population. So all the cancer cells, known as blasts, are Clever-1 positive. So in the context of myelodysplastic syndrome, we're not just activating the immune system, we're also depriving cancer of its main source of protection. And this is likely why we are seeing such good results. We believe we are one of the first drugs to tackle the core biology of myelodysplastic syndrome, which makes it such a difficult disease to treat. Next slide please. So, what has recently happened? We have completed a phase one/two open-label study. Follow-up data has continued to come in, and it has been strong, confirming sustainable benefit for patients. Meanwhile, in the area of high-risk myelodysplastic syndrome, there have unfortunately been a lot of phase three failures.
But these come with important learnings which we have now taken into consideration, and they have guided us to put together a Phase 2b study in frontline, HR MDS. Based on that, we have completed one of the biggest financial rounds in Finland for biotechs, 40 million raised through a rights offering, and now we are funded to deliver this phase 2b readout. But on top of that, we will also be delivering phase 1/2 data in a number of solid tumor indications. So truly exciting times ahead.
Next slide please. I would like to take this moment to look at the landscape of high-risk myelodysplastic syndrome. The absolute vacuum of new treatment options has brought a lot of pharma companies into this area. So, there is actually a lot of development ongoing. It is primarily early stage. So, we have now evolved as one of the leading candidates in this space, and especially a leading candidate when it comes to disease-modifying agents. What we are showing here on the screen is that some of these attempts still rely on targets that have unfortunately failed in this space, such as CD47, BCL-2 inhibitors, and also kinase inhibitors. But there is a nice fleet of new immunomodulating agents coming to this area, for example, a Galectin-9 inhibitor or a PI3K gamma inhibitor. So I would say now, finally, the field of MDS has understood that we cannot continue giving toxic cytopenic drugs to these patients. We need something truly disease-modifying. And we are leading this new era. Next slide please. And what really makes our drug, Bexmarilimab, different—and I would say special—is the mode of action we have demonstrated. And then the safety profile that comes with the mode of action. We are not a cytotoxic agent causing anemia and neutropenia. Actually, it looks like we are making it better. So here in this slide in gray, you can see what is expected from a safety profile for the market-leading hypomethylating agent, azacitidine. But when we add bexmarilimab to azacitidine, we are not actually increasing these safety issues. We are actually making them better because we are, again, one of the rare, possibly only drugs that improves cancer cell killing while also inducing the production of healthy blood cells. Next slide please. So that was the safety and this is the efficacy. What are we looking at here in the front line where patients receive azacitidine. Also, in the first-line setting, one can historically expect a 16% to 17% complete remission rate, and in recent trials, up to 20%. And that is ultimately what you want to achieve for these patients. Complete remission means the cancer is gone and blood counts are back to normal. What we have seen in our open-label phase 1/2 trial is a 45% complete remission (CR) rate, which is outstanding. Still, survival is pretty mature in the front-line setting, but we have just recently reported the first data cut, and we will be presenting those in upcoming medical conferences now in the last lines and in the relapsed refractory setting where nothing seems to work. Salvage treatment usually only provides 5 to 6 months of median survival. We are expecting to double that. So again sustainable benefit for patients. Next slide please. So we are entering late-stage development. We have further strengthened our team during H1. Chief Technical Officer Mr. Heikki Jouttijärvi has started with decades of experience bringing drugs to market from a supply chain and manufacturing perspective. Just as important as the clinical trials is the manufacturing of the drug and preparing it for marketing approval. We have partnered with Parexel, a world-leading global contract research organization, to deliver the Phase 2b study. We are very happy with this partnership and it has gotten off to a good start. Then on the business development side, we have further strengthened our team with George Golumbeski joining our board. He brings decades of experience from business development across the industry. We are extremely happy with our team.
Next slide please. So recently, what is now coming up? Then, we have announced that the BLAZE study in checkpoint refractory lung and melanoma has gained regulatory approval. Also, the BEXERA study in soft tissue sarcoma has gained regulatory approval. The FINPROVE study in breast cancer will not be proceeding. It will require a standalone study, and we are focusing our resources on our main myelodysplastic syndrome program. Instead of putting together a standalone study for breast cancer, we are focusing on our AML study. BEAM-X is also progressing, and currently in protocol development is the further relapsed/refractory myelodysplastic syndrome study with the City of Hope, utilizing oral hypomethylating agents, the newcomer to the area. So, a rather vast pipeline is producing a lot of new data for such a small company.
Next slide please. What can our audience and investors look forward to for H2? As I mentioned, we just completed the first data cut for the survival readout in the frontline high-risk MDS population. The data is trending well. We will report further follow-up data in upcoming conferences. And this is why this data cut was performed. Also, at an upcoming major conference, we will be reporting more mature data from the first-in-human solid tumor trial and providing updates on how our trials are progressing in solid tumors. So the scientific foundation of Clever-1 continues to strengthen and broaden during the second half.
Next slide please. So what can one anticipate further from a news flow? There will now be a series of first patient-in announcements in H2 for a number of these trials. There will be further follow-up data from our existing trials. But then comes the most exciting year, 2027, when a lot of this data will be coming out from these trials. So very exciting times ahead. We have worked extremely hard during H1 to get these trials started. They are starting. I couldn't be more excited. Next slide please. So, next we will give the floor to our Chief Financial Officer to talk about the financial results.